|
|
|
|
LEADER |
04546nam a2200961Ia 4500 |
001 |
10.1002-jcla.23938 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a Long non-coding RNA growth arrest-specific 5 and its targets, microRNA-21 and microRNA-140, are potential biomarkers of allergic rhinitis
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23938
|
520 |
3 |
|
|a Objective: Long non-coding RNA growth arrest-specific 5 (lnc-GAS5) and its targets (microRNA [miR]-21 and miR-140) are involved in the development and progression of allergic rhinitis (AR). However, the correlation of lnc-GAS5 with miR-21 and miR-140 and their associations with disease risk, symptom severity, and Th1/Th2 cytokines in AR remain unclear. Thus, this study aimed to investigate this topic. Methods: In total, 120 patients with AR and 60 controls were recruited. Nasal-mucosa tissues were collected from all participants. Lnc-GAS5, its targets (miR-21 and miR-140), interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-10 were detected by reverse-transcription quantitative polymerase chain reaction. Results: Lnc-GAS5 was elevated, while miR-21 and miR-140 was downregulated in AR patients than in controls (p < 0.001). In AR patients, lnc-GAS5 was negatively correlated with miR-21 (p < 0.001), miR-140 (p < 0.001), IFN-γ (p = 0.019), and IL-2 (p = 0.039) and positively correlated with IL-4 (p = 0.004) and IL-10 (p < 0.001), individual nasal symptom scores (INSSs) for itching, sneezing, and congestion (p < 0.05), and total nasal symptom score (TNSS) (p < 0.001). Moreover, miR-21 and miR-140 were negatively correlated with some INSSs, total TNSS score, and IL-10 and positively correlated with IFN-γ and IL-2 (p < 0.05). Conclusion: Lnc-GAS5 is negatively correlated with that of its targets (miR-21 and miR-140) in AR; meanwhile, lnc-GAS5, miR-21, and miR-140 are correlated with disease risk, symptom severity, and Th1/Th2 imbalance in AR, suggesting the potential of these biomarkers in the development and progression of AR. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Adult
|
650 |
0 |
4 |
|a allergic rhinitis
|
650 |
0 |
4 |
|a allergic rhinitis
|
650 |
0 |
4 |
|a allergic rhinitis
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a biological marker
|
650 |
0 |
4 |
|a Biomarkers
|
650 |
0 |
4 |
|a clinical feature
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a cytokine
|
650 |
0 |
4 |
|a Cytokines
|
650 |
0 |
4 |
|a disease exacerbation
|
650 |
0 |
4 |
|a disease severity
|
650 |
0 |
4 |
|a down regulation
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a gamma interferon
|
650 |
0 |
4 |
|a GAS5 long non-coding RNA, human
|
650 |
0 |
4 |
|a gene expression
|
650 |
0 |
4 |
|a genetic association
|
650 |
0 |
4 |
|a genetic correlation
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human tissue
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a immunoglobulin E
|
650 |
0 |
4 |
|a individual nasal symptom score
|
650 |
0 |
4 |
|a interleukin 10
|
650 |
0 |
4 |
|a interleukin 2
|
650 |
0 |
4 |
|a interleukin 4
|
650 |
0 |
4 |
|a long non coding RNA growth arrest specific 5
|
650 |
0 |
4 |
|a long non-coding RNA growth arrest-specific 5
|
650 |
0 |
4 |
|a long untranslated RNA
|
650 |
0 |
4 |
|a long untranslated RNA
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a microRNA
|
650 |
0 |
4 |
|a microRNA
|
650 |
0 |
4 |
|a microRNA 140
|
650 |
0 |
4 |
|a microRNA 21
|
650 |
0 |
4 |
|a microRNA-140
|
650 |
0 |
4 |
|a microRNA-21
|
650 |
0 |
4 |
|a MicroRNAs
|
650 |
0 |
4 |
|a Mirn140 microRNA, human
|
650 |
0 |
4 |
|a MIRN21 microRNA, human
|
650 |
0 |
4 |
|a nose obstruction
|
650 |
0 |
4 |
|a protein blood level
|
650 |
0 |
4 |
|a protein expression
|
650 |
0 |
4 |
|a pruritus
|
650 |
0 |
4 |
|a real time reverse transcription polymerase chain reaction
|
650 |
0 |
4 |
|a respiratory tract disease assessment
|
650 |
0 |
4 |
|a Rhinitis, Allergic
|
650 |
0 |
4 |
|a rhinorrhea
|
650 |
0 |
4 |
|a risk
|
650 |
0 |
4 |
|a RNA, Long Noncoding
|
650 |
0 |
4 |
|a sneezing
|
650 |
0 |
4 |
|a Th1 Th2 balance
|
650 |
0 |
4 |
|a Th1&Th2 cells
|
650 |
0 |
4 |
|a total nasal symptom score
|
650 |
0 |
4 |
|a unclassified drug
|
650 |
0 |
4 |
|a young adult
|
650 |
0 |
4 |
|a Young Adult
|
700 |
1 |
|
|a Cen, R.
|e author
|
700 |
1 |
|
|a Chen, Y.
|e author
|
700 |
1 |
|
|a Song, J.
|e author
|
700 |
1 |
|
|a Wang, T.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|